利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

89 条记录 (耗时 0.053 秒)

    CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
    31.
    发明申请
    CYCLIC P3 TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS 有权
    循环P3三磷酸腺嘌呤C丝氨酸蛋白酶抑制剂

    公开(公告)号：US20080267916A1

    公开(公告)日：2008-10-30

    申请号：US11740440

    申请日：2007-04-26

    申请人： Yonghua Gai ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    发明人： Yonghua Gai ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： C07K5/08 ,  A61K38/06 ,  A61P31/12 ,  A61K38/21

    CPC分类号： A61K38/212 ,  A61K38/215 ,  C07K5/0821 ,  A61K2300/00

    摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors
    32.
    发明申请
    Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors 有权
    喹喔啉基大环丙型肝炎病毒丝氨酸蛋白酶抑制剂

    公开(公告)号：US20070299078A1

    公开(公告)日：2007-12-27

    申请号：US11768723

    申请日：2007-06-26

    申请人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Or ,  Zhe Wang

    发明人： Deqiang Niu ,  Dong Liu ,  Joel Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Or ,  Zhe Wang

    IPC分类号： A61K31/498 ,  A61K31/4985 ,  A61P31/12 ,  C07D245/04

    CPC分类号： C07D245/04 ,  A61K38/212 ,  A61K38/215 ,  C07D403/12 ,  A61K2300/00

    摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Quinoxalinyl tripeptide hepatitis C virus inhibitors
    35.
    发明授权
    Quinoxalinyl tripeptide hepatitis C virus inhibitors 有权
    喹喔啉三肽丙型肝炎病毒抑制剂

    公开(公告)号：US07635683B2

    公开(公告)日：2009-12-22

    申请号：US11499917

    申请日：2006-08-04

    申请人： Yonghua Gai ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    发明人： Yonghua Gai ,  Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/06

    CPC分类号： C07K5/0808 ,  A61K38/00

    摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS
    38.
    发明申请
    ARYLPIPERIDINYL AND ARYLPYRROLIDINYL TRIPEPTIDE HEPATITIS C SERINE PROTEASE INHIBITORS 审中-公开
    抗坏血酸乙酰胆碱和抗坏血酸乙酰胆碱酯酶蛋白酶抑制剂

    公开(公告)号：US20080317712A1

    公开(公告)日：2008-12-25

    申请号：US12108628

    申请日：2008-04-24

    申请人： Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    发明人： Deqiang Niu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/21 ,  C07D401/04 ,  A61K38/05 ,  C07D403/04 ,  A61P31/12 ,  C07D413/14

    CPC分类号： C07D401/04 ,  A61K38/00 ,  C07D401/14 ,  C07D403/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

    摘要： The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明涉及抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶活性的式I化合物或其药学上可接受的盐，酯或前药。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

    Bicyclic 9a-azalide derivatives
    39.
    发明授权
    Bicyclic 9a-azalide derivatives 失效
    双环9a-azalide衍生物

    公开(公告)号：US07402568B2

    公开(公告)日：2008-07-22

    申请号：US11236043

    申请日：2005-09-27

    申请人： Yat Sun Or ,  Yao-Ling Qiu ,  Guoqiang Wang ,  Deqiang Niu ,  Ly Tam Phan

    发明人： Yat Sun Or ,  Yao-Ling Qiu ,  Guoqiang Wang ,  Deqiang Niu ,  Ly Tam Phan

    IPC分类号： A61K31/70 ,  C07H17/08

    CPC分类号： C07H17/08

    摘要： The present invention discloses compounds of formulae I and II, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes process by which to make the compounds of the present invention.

    摘要翻译： 本发明公开了式I和II的化合物或其药学上可接受的盐，酯或前药：其表现出抗菌性质。 本发明还涉及包含上述化合物的药物组合物，用于给予需要抗生素治疗的受试者。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的细菌感染的方法。 本发明还包括制备本发明化合物的方法。

    MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS
    40.
    发明申请
    MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS 有权
    大环氧合酶抑制剂C蛋白酶抑制剂

    公开(公告)号：US20070281885A1

    公开(公告)日：2007-12-06

    申请号：US11759080

    申请日：2007-06-06

    申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

    IPC分类号： A61K38/12 ,  C07K5/12

    CPC分类号： A61K38/4886 ,  A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K38/45 ,  A61K38/52 ,  C07K5/0804 ,  C07K5/0812 ,  C07K7/06 ,  A61K2300/00

    摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

    摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。